
    
      The prospective volunteers will be screened and HLA typed for Class I MHC haplotypes. Only
      volunteers possessing HLA alleles A33, B8, B27, B35 or Bw62 or any combination thereof will
      be enrolled in the study. Subjects will be allocated to 1 of 2 study groups. Group 1 will
      receive 70 mcg of P3C541b or the placebo and Group II will receive 350 mcg of P3C541b or the
      placebo. NOTE: Enrollment for Group II wil not begin until at least 5 Group I participants
      have reached day 14 without serious adverse events.
    
  